JohanssonIEdnerMDahlströmU, et al.Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. Heart2015; 101: 1139–1148.
2.
ZinmanBWannerCLachinJM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med2015; 373: 2117–2128.
3.
NealBPerkovicVMahaffeyKW, et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med2017; 377: 644–657.
4.
WiviottSDRazIBonacaMP, et al.DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med2019; 380: 347–357.
5.
UsmanMSSiddiqiTJMemonMM, et al.Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol2018; 25: 495–502.
6.
HigginsJPAltmanDGGøtzschePC, et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928–d5928.
7.
Khan MS, Usman MS, Siddiqi TJ, et al. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: a systematic review and meta-analysis. Eur J Prev Cardiol. 2019; 26: 1680–1682.
8.
ButlerJHamoCEFilippatosG, et al.EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail2017; 19: 1390–1400.
9.
NorhammarAMellbinLCosentinoF. Diabetes: prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol2017; 24: 52–60.
10.
DaviesMJD’AlessioDAFradkinJ, et al.Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care2018; 41: 2669–2701.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
